
Please try another search
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Name | Age | Since | Title |
---|---|---|---|
Nicole Holden | 49 | 2021 | Independent Non-Executive Director |
Heinrich Dreismann | 70 | 2021 | Independent Non-Executive Chairman |
Guido Baechler | 59 | 2021 | CEO & Executive Director |
Soren Thestrup-Nielsen | - | 2021 | Member of Strategic Advisory Board |
Karen L. Richards | - | - | Member of Strategic Advisory Board |
Michele Pedrocchi | - | 2022 | Member of Strategic Advisory Board |
Hans Johan Hekland | 67 | 2021 | Independent Non-Executive Director |
Rainer Metzger | - | 2022 | Member of Strategic Advisory Board |
Gregory J. Tibbitts | 58 | 2022 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review